{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:56:40Z","timestamp":1781287000874,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"DOI":"10.7759\/cureus.110745","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:01:39Z","timestamp":1781283699000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Efficacy of Sirolimus in Skeletal Manifestations of Gorham-Stout Disease in Adults: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Michal","family":"Mierzejewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Olizarowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Kania-Bonicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Majewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Szczepanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03649-9","article-title":"Clinical features and current management experience in Gorham-Stout disease: a systematic review","volume":"20","author":"Zhou Z","year":"2025","unstructured":"Zhou Z, Qiu T, Zhou J, et al.. Clinical features and current management experience in Gorham-Stout disease: a systematic review. Orphanet J Rare Dis. 2025, 20:134. 10.1186\/s13023-025-03649-9","journal-title":"Orphanet J Rare Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2018.0850","article-title":"Generalized lymphatic anomaly and Gorham-Stout disease: overview and recent insights","volume":"8","author":"Ozeki M","year":"2019","unstructured":"Ozeki M, Fukao T. Generalized lymphatic anomaly and Gorham-Stout disease: overview and recent insights. Adv Wound Care (New Rochelle). 2019, 8:230-45. 10.1089\/wound.2018.0850","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EOR-21-0083","article-title":"Current concepts from diagnosis to management in Gorham-Stout disease: a systematic narrative review of about 350 cases","volume":"7","author":"Angelini A","year":"2022","unstructured":"Angelini A, Mosele N, Pagliarini E, Ruggieri P. Current concepts from diagnosis to management in Gorham-Stout disease: a systematic narrative review of about 350 cases. EFORT Open Rev. 2022, 7:35-48. 10.1530\/EOR-21-0083","journal-title":"EFORT Open Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02704-7","article-title":"The spectrum of imaging manifestations of Gorham-Stout disease: a novel dynamic contrast-enhanced MR lymphangiography","volume":"18","author":"Lee Y","year":"2023","unstructured":"Lee Y, Lee S, Hur S, et al.. The spectrum of imaging manifestations of Gorham-Stout disease: a novel dynamic contrast-enhanced MR lymphangiography. Orphanet J Rare Dis. 2023, 18:96. 10.1186\/s13023-023-02704-7","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(83)90185-8","article-title":"Perspectives on massive osteolysis. Report of a case and review of the literature","volume":"55","author":"Heffez L","year":"1983","unstructured":"Heffez L, Doku HC, Carter BL, Feeney JE. Perspectives on massive osteolysis. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1983, 55:331-43. 10.1016\/0030-4220(83)90185-8","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.5.8626854","article-title":"Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease","volume":"81","author":"Devlin RD","year":"1996","unstructured":"Devlin RD, Bone HG 3rd, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 1996, 81:1893-7. 10.1210\/jcem.81.5.8626854","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3077","article-title":"Lymphatic endothelial cells produce M-CSF, causing massive bone loss in mice","volume":"32","author":"Wang W","year":"2017","unstructured":"Wang W, Wang H, Zhou X, et al.. Lymphatic endothelial cells produce M-CSF, causing massive bone loss in mice. J Bone Miner Res. 2017, 32:939-50. 10.1002\/jbmr.3077","journal-title":"J Bone Miner Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34323","article-title":"VEGF-C promotes the development of lymphatics in bone and bone loss","volume":"7","author":"Hominick D","year":"2018","unstructured":"Hominick D, Silva A, Khurana N, et al.. VEGF-C promotes the development of lymphatics in bone and bone loss. Elife. 2018, 7:e34323. 10.7554\/eLife.34323","journal-title":"Elife"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-020-0794-y","article-title":"A somatic activating KRAS variant identified in an affected lesion of a patient with Gorham-Stout disease","volume":"65","author":"Nozawa A","year":"2020","unstructured":"Nozawa A, Ozeki M, Niihori T, Suzui N, Miyazaki T, Aoki Y. A somatic activating KRAS variant identified in an affected lesion of a patient with Gorham-Stout disease. J Hum Genet. 2020, 65:995-1001. 10.1038\/s10038-020-0794-y","journal-title":"J Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149831","article-title":"KRAS-driven model of Gorham-Stout disease effectively treated with trametinib","volume":"6","author":"Homayun-Sepehr N","year":"2021","unstructured":"Homayun-Sepehr N, McCarter AL, Helaers R, et al.. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib. JCI Insight. 2021, 6:e149831. 10.1172\/jci.insight.149831","journal-title":"JCI Insight"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1654497","article-title":"Exploring the genetic alterations of Gorham-Stout disease","volume":"16","author":"Pagliarosi O","year":"2025","unstructured":"Pagliarosi O, Pepe J, Del Fattore A, Rossi M. Exploring the genetic alterations of Gorham-Stout disease. Front Endocrinol (Lausanne). 2025, 16:1654497. 10.3389\/fendo.2025.1654497","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01277-x","article-title":"Gorham-Stout case report: a multi-omic analysis reveals recurrent fusions as new potential drivers of the disease","volume":"15","author":"Y\u00e9benes Mayordomo M","year":"2022","unstructured":"Y\u00e9benes Mayordomo M, Al Shboul S, G\u00f3mez-Herranz M, et al.. Gorham-Stout case report: a multi-omic analysis reveals recurrent fusions as new potential drivers of the disease. BMC Med Genomics. 2022, 15:128. 10.1186\/s12920-022-01277-x","journal-title":"BMC Med Genomics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181353","article-title":"Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly","volume":"216","author":"Rodriguez-Laguna L","year":"2019","unstructured":"Rodriguez-Laguna L, Agra N, Iba\u00f1ez K, et al.. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly. J Exp Med. 2019, 216:407-18. 10.1084\/jem.20181353","journal-title":"J Exp Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2019.1709716","article-title":"Gorham-Stout disease: good results of bisphosphonate treatment in 6 of 7 patients","volume":"91","author":"Schneider KN","year":"2020","unstructured":"Schneider KN, Masthoff M, Gosheger G, et al.. Gorham-Stout disease: good results of bisphosphonate treatment in 6 of 7 patients. Acta Orthop. 2020, 91:209-14. 10.1080\/17453674.2019.1709716","journal-title":"Acta Orthop"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.01.006","article-title":"Radiation therapy for Gorham-Stout syndrome: results of a national patterns-of-care study and literature review","volume":"81","author":"Heyd R","year":"2011","unstructured":"Heyd R, Micke O, Surholt C, et al.. Radiation therapy for Gorham-Stout syndrome: results of a national patterns-of-care study and literature review. Int J Radiat Oncol Biol Phys. 2011, 81:e179-85. 10.1016\/j.ijrobp.2011.01.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams DM","year":"2016","unstructured":"Adams DM, Trenor CC 3rd, Hammill AM, et al.. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016, 137:e20153257. 10.1542\/peds.2015-3257","journal-title":"Pediatrics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27614","article-title":"Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease","volume":"66","author":"Ricci KW","year":"2019","unstructured":"Ricci KW, Hammill AM, Mobberley-Schuman P, et al.. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. Pediatr Blood Cancer. 2019, 66:e27614. 10.1002\/pbc.27614","journal-title":"Pediatr Blood Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1335469","article-title":"Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial","volume":"11","author":"Ozeki M","year":"2024","unstructured":"Ozeki M, Endo S, Yasue S, et al.. Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial. Front Med (Lausanne). 2024, 11:1335469. 10.3389\/fmed.2024.1335469","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-018-0028-4","article-title":"mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1","volume":"1","author":"Huynh H","year":"2018","unstructured":"Huynh H, Wan Y. mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1. Commun Biol. 2018, 1:29. 10.1038\/s42003-018-0028-4","journal-title":"Commun Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c01289","article-title":"Rapamycin inhibits osteoclastogenesis and prevents LPS-induced alveolar bone loss by oxidative stress suppression","volume":"8","author":"Feng C","year":"2023","unstructured":"Feng C, Liu Y, Zhang BY, et al.. Rapamycin inhibits osteoclastogenesis and prevents LPS-induced alveolar bone loss by oxidative stress suppression. ACS Omega. 2023, 8:20739-54. 10.1021\/acsomega.3c01289","journal-title":"ACS Omega"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref22","article-title":"Chapter 7. Systematic reviews of etiology and risk","author":"Moola S","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Chapter 7. Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. Aromataris E, Munn Z (ed): JBI, Adelaide, South Australia; 2020. 219-71."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5826\/mrm.2024.957","article-title":"Gorham-Stout disease and multiple cervical lymphangiomas: case report","volume":"19","author":"Amezquita MA","year":"2024","unstructured":"Amezquita MA, Sua LF, Garcia CA, Fern\u00e1ndez-Trujillo L. Gorham-Stout disease and multiple cervical lymphangiomas: case report. Multidiscip Respir Med. 2024, 19:10.5826\/mrm.2024.957","journal-title":"Multidiscip Respir Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000514","article-title":"Gorham-Stout disease successfully treated with sirolimus and zoledronic acid therapy","volume":"38","author":"Cramer SL","year":"2016","unstructured":"Cramer SL, Wei S, Merrow AC, Pressey JG. Gorham-Stout disease successfully treated with sirolimus and zoledronic acid therapy. J Pediatr Hematol Oncol. 2016, 38:e129-32. 10.1097\/MPH.0000000000000514","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.25100\/cm.v47i4.2406","article-title":"Sirolimus on Gorham-Stout disease. Case report","volume":"47","author":"Garc\u00eda V","year":"2016","unstructured":"Garc\u00eda V, Alonso-Claudio G, G\u00f3mez-Hern\u00e1ndez MT, et al.. Sirolimus on Gorham-Stout disease. Case report. Colomb Med. 2016, 47:213-6.","journal-title":"Colomb Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.21037\/fomm-23-80","article-title":"Reossification of Gorham-Stout disease of the maxilla and the pterygoid process during medical treatment with sirolimus, zoledronic acid and vitamin D: a case report","volume":"7","author":"Gvetadze S","year":"2025","unstructured":"Gvetadze S, Ilkaev K, Roshchina E, et al.. Reossification of Gorham-Stout disease of the maxilla and the pterygoid process during medical treatment with sirolimus, zoledronic acid and vitamin D: a case report. Front Oral Maxillofac Med. 2025, 7:6. 10.21037\/fomm-23-80","journal-title":"Front Oral Maxillofac Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12890\/2021_002740","article-title":"Gorham-Stout disease with clinical response to sirolimus treatment","volume":"8","author":"Forero Saldarriaga S","year":"2021","unstructured":"Forero Saldarriaga S, Vallejo C, Urrea Pineda L, Osma A, Bonilla Gonzalez C. Gorham-Stout disease with clinical response to sirolimus treatment. Eur J Case Rep Intern Med. 2021, 8:002740. 10.12890\/2021_002740","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237638","article-title":"Gorham-Stout disease of the mandible, manubrium and cervical spine presenting as bilateral chylothorax","volume":"14","author":"Thompson AA","year":"2021","unstructured":"Thompson AA, Patrawala S. Gorham-Stout disease of the mandible, manubrium and cervical spine presenting as bilateral chylothorax. BMJ Case Rep. 2021, 14:e237638. 10.1136\/bcr-2020-237638","journal-title":"BMJ Case Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191811692","article-title":"Difficult therapeutic decisions in Gorham-Stout disease\u2014case report and review of the literature","volume":"19","author":"Wojciechowska-Durczynska K","year":"2022","unstructured":"Wojciechowska-Durczynska K, Zygmunt A, Mikulak M, Ludwisiak M, Lewinski A. Difficult therapeutic decisions in Gorham-Stout disease\u2014case report and review of the literature. Int J Environ Res Public Health. 2022, 19:11692. 10.3390\/ijerph191811692","journal-title":"Int J Environ Res Public Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2025.102195","article-title":"Effective management of refractory chylothorax associated with elderly onset Gorham-Stout disease: a case report","volume":"55","author":"Yamaki H","year":"2025","unstructured":"Yamaki H, Ejima M, Takeguchi T, et al.. Effective management of refractory chylothorax associated with elderly onset Gorham-Stout disease: a case report. Respir Med Case Rep. 2025, 55:102195. 10.1016\/j.rmcr.2025.102195","journal-title":"Respir Med Case Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3171\/2018.5.PEDS1859","article-title":"Intracranial hypotension and hypertension: reversible Chiari malformation due to dynamic cerebrospinal fluid abnormalities in Gorham-Stout disease. Case report","volume":"22","author":"Yoshimoto S","year":"2018","unstructured":"Yoshimoto S, Takai K, Takahashi K, Yasui T, Taniguchi M. Intracranial hypotension and hypertension: reversible Chiari malformation due to dynamic cerebrospinal fluid abnormalities in Gorham-Stout disease. Case report. J Neurosurg Pediatr. 2018, 22:508-12. 10.3171\/2018.5.PEDS1859","journal-title":"J Neurosurg Pediatr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler JJ","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, et al.. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358:140-51. 10.1056\/NEJMoa063564","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2793","article-title":"Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells","volume":"18","author":"Xian L","year":"2012","unstructured":"Xian L, Wu X, Pang L, et al.. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med. 2012, 18:1095-101. 10.1038\/nm.2793","journal-title":"Nat Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.24875\/BMHIM.23000015","article-title":"Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment","volume":"80","author":"Barnes-Salda\u00f1a F","year":"2023","unstructured":"Barnes-Salda\u00f1a F, Venegas-Andrade A, Colin-Mart\u00ednez \u00d3, Lizardo-Rodr\u00edguez A, Garc\u00eda-Romero MT, Dur\u00e1n-McKinster C. Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment. Bol Med Hosp Infant Mex. 2023, 80:217-21. 10.24875\/BMHIM.23000015","journal-title":"Bol Med Hosp Infant Mex"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1434493","article-title":"Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients","volume":"12","author":"Neirotti A","year":"2024","unstructured":"Neirotti A, Barat V, Coppo P, et al.. Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients. Front Pediatr. 2024, 12:1434493. 10.3389\/fped.2024.1434493","journal-title":"Front Pediatr"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00810-9","article-title":"Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation","volume":"42","author":"Nguyen LS","year":"2019","unstructured":"Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf. 2019, 42:813-25. 10.1007\/s40264-019-00810-9","journal-title":"Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500749-therapeutic-efficacy-of-sirolimus-in-skeletal-manifestations-of-gorham-stout-disease-in-adults-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:01:43Z","timestamp":1781283703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500749-therapeutic-efficacy-of-sirolimus-in-skeletal-manifestations-of-gorham-stout-disease-in-adults-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.110745","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}